Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTI BioPharma’s Pacritinib Meets One Co-Primary Endpoint, Just Misses Another, In PERSIST-2

Executive Summary

The US company is encouraged by top-line efficacy Phase III results showing pacritinib was effective in high-risk myelofibrosis patients with low platelet counts, and has said it is working with the FDA to lift the clinical hold imposed earlier this year because of side-effect concerns.

Advertisement

Related Content

CTI's Approval Prospects For Pacritinib In Myelofibrosis Look To Be Improving
Finance Watch: Summer Slowdown Begins Ahead Of BIO, But Two IPOs Launched
Misery In Myelofibrosis: Pacritinib Setback A Boost For Jakafi
Gilead's Late-Stage R&D Misfire Gives Respite To Competing Myelofibrosis Therapies
Shire Exits Biosimilars, Streamlines Oncology Business
CTI/Baxalta Withdraw Pacritinib NDA Following More Deaths
Sanofi Oncology Strategy: A New Lease On Cancer R&D
CTI Lands Baxter As Pacritinib Partner To Try To Reach Finish Line

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097206

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel